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conclusion, haploidentical HSCT with post-transplant cyclo-
phosphamide is a feasible alternative for X-ALD lacking a
suitable matched donor. Graft failure is still an obstacle that
has to be better prevented.245
Busulfan, Melphalan, and Thiotepa Conditioning for
Allogeneic Hematopoietic Stem Cell Transplantation
(HSCT) of Pediatric Patients with Acute Leukemia and
Central Nervous System (CNS) Disease
Christopher J. Forlenza 1, Rachel Kobos 2, Nancy A. Kernan 2,
Andromachi Scaradavou 2, Susan E. Prockop 2, Kevin Curran 2,
Neerav Shukla 1, Peter G. Steinherz 1, Richard O’Reilly 2,
Farid Boulad 2. 1 Department of Pediatrics, Memorial
Sloan-Kettering Cancer Center, New York, NY; 2 Department of
Pediatrics, Bone Marrow Transplant Service, Memorial
Sloan-Kettering Cancer Center, New York, NY
The standard of care for the transplantation of pediatric pa-
tients with acute leukemia and prior CNS disease is the use of
total body irradiation (TBI), plus a CNS radiation therapy (RT)
boost. However, the late effects of radiation can be pro-
hibitive, especially in younger children or those who have
previously received radiation therapy. We developed a
chemotherapy-only cytoreductive regimenwith the intent of
targeting the CNS with agents that can readily cross the
blood brain barrier and achieve high concentrations. We
used the combination of Busulfan (1mg/kg every 6 hours x 3
days), melphalan (50mg/m2/day x 2 days), and thiotepa IV
(8.3mg/kg/day or 250mg/m2/day x 2 days).
We treated six patients with acute myelogenous leukemia
(AML (N¼5) or acute lymphoblastic leukemia (ALL) with this
regimen from July 1999 and February 2013. The median age
at the time of HSCT was 2.8 years (range 1.7 to 13.4 years).
Patients were in complete CNS remission (CR) CR1 (N¼1),
CR2 (N¼3), CR3 (N¼1), and CR8 (N¼1). All six patients were
treated with multiple intrathecal chemotherapy agents prior
to transplant. Four of six patients received cranio-spinal
radiation therapy (RT) prior to HSCT; RT was required to
achieve a CNS CR in 3 of 4 of these patients. One patient
received CNS RT post HSCT, while one patient was
completely spared CNS RT.
Donors and grafts included unrelated mismatched umbilical
double cord transplants (N¼4) and matched related T-cell
depleted bone marrow transplants (N¼2). All six patients
engrafted. One patient succumbed to infectious complica-
tions nearly 2 months post HSCT. The ﬁve other patients are
still alive without marrow or CNS relapse at a median follow-
up of 19.4 months post HSCT (range: 11.1 to 149.5 months) .
While this represents a small patient series, this data pro-
vides evidence for a promising transplant chemotherapy-
only regimen for the transplantation of pediatric patients
with acute leukemia and CNS disease who are unable to
receive TBI, and will be the focus of a larger prospective
study.246
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2 Christian Medical College, Vellore, IndiaAcute GVHD (aGVHD) remains a major challenge in alloge-
neic stem cell transplantation and is associated with signif-
icant morbidity. Though it is associated with a graft versus
leukemia effect in SCT for malignant disorders, it has no
beneﬁt in SCT for non-malignant disorders such as thalas-
semia major.
This is a retrospective analysis of 321 patients who under-
went allogeneic SCT for Thalassemia Major at our centre
between Jan 1991 and Dec 2011. This included 205 males and
116 females with a median age of 7 years (range: 2 - 24).
Patients who expired prior to 2 weeks or had primary graft
rejection were excluded from this analysis. 6.9% of patients
were in Lucarelli Class I, 36.4% in Class II, and 56.7% in Class
III. Donors included matched sibling (n ¼ 299) or other
family donors (n ¼ 22). Conditioning regimen was predom-
inantly Busulfan based (n ¼ 274) while 47 patients received
treosulfan based conditioning. Graft source was mainly bone
marrow (n ¼ 286) while GVHD prophylaxis mainly was
Cyclosporine with short course methotrexate (n ¼ 301).
Acute GVHD (Grade I e IV) occurred in 125 patients (38.9%),
grade II-IV in 28% and grade IV in 5.3%. Donor age (p¼ 0.062),
type of conditioning regimen (p ¼ 0.07), number of doses of
methotrexate administered (p ¼ 0.05), presence of veno-
occlusive disease (VOD) [p ¼ 0.016] and time to neutrophil
engraftment (p ¼ 0.027) were found to be signiﬁcant risk
factors for acute GVHD on a univariate analysis but only VOD
(p ¼ 0.017) and donor age (p ¼ 0.044) remained signiﬁcant
on multivariate analysis. Resolution of GVHD was seen in
90.4% while 9.6% died either due to GVHD or infection. The
3 year overall survival was 80%  2.3% in patients with
GVHD compared to 81.1%  2.9% in patients without GVHD
(p ¼ 0.422).
Acute GVHD is seen in 39% of patients undergoing SCT for
thalassemia major but it does not have a signiﬁcant impact
on overall survival.247
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Background: Hemorrhagic cystitis (HC) is a fairly common
and potentially severe complication observed after hemato-
poietic Stem cell transplantation (HSCT) which may result in
morbidity and extended hospitalization. Its incidence in pe-
diatric patients is unknown.
Methods: We performed a retrospective study on 900 pe-
diatric patients who received HSCT after myeloablative or
reduced intensity conditioning during 1992 e 2011 in our
center. In all, sixty patients (43 male &17 female) developed
HC: early in 35 patients and late in 25 patients. Median age of
patients was 9.19years (range: 2-15). Major thaassemia (45%)
and ALL (18.30%) were most common cause of trans-
plantation. Patients received transplant frommatched donor
(n¼45), 2 locus mismatched (n¼8) and HLA-haploidentical
(n¼7). The source of stem cell were peripheral blood (n¼40),
bone marrow (n¼15) and cord blood (n¼5). Majority of pa-
tient (83.3%) received BU/CY conditioning regiment.
Results: The prevalence of HC was 6.7% in our patients who
all of them had received allogenic HSCT. 4 patients had
pervious history of HC. Acute graft versus host disease
(GvHD) occurred in 46(76.7%) patients. There was no sig-
niﬁcant correlation between the grade of acute GvHD and
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etiology for one or more viruses was found in 40 cases (CMV,
HSV& BK). HC was managed with supportive care (blood and
platelet transfusion, hydration and irrigation) in all patients.
4 of the patients required surgical interventions and cys-
tectomy. 4 years Overall survival of patients was 56%. Main
cause of death were sever HC (n¼11) and disease relapse
(n¼9).
Conclusion: HC is caused by the interaction of several
conditions such as donor type and preparative regimen in-
tensity. This study shows that young age correlated with a
lower incidence of severe HC. A prospective study is neces-
sary to clarify the association between clinical factors such as
age in the development of severe HC following HSCT in
children.248
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Introduction: Hematopoietic stem cell transplantation
(HSCT) is considered the only curative treatment ofmalignant
infantile osteopetrosis(MIOP). This study evaluates the
radiologic evolution of skeletal changes after HSCT in children
with MIOP.
Methods: Twelve patients(8 male & 4 female, median age of
14.5 months) with proved MIOP underwent HSCT. Patients
received transplant from relative matched donor(n¼9),
unrelated matched(n¼1), unrelated mismatched cord
blood(n¼1) and HLA-haploidentical relative(n¼1). The
source of stem cell were bone marrow(n¼7), peripheral
blood(n¼4) and cord blood(n¼1). Baseline, 6th and 12th
month post-HSCT whole body bone surveys were per-
formed. All patients survived except one who died at 8
months due to infection.
Results: Baseline corticomedullary differentiation was not
detectable in any patient, however by 6th month it was
perceivable in 3(p-value: 0.25) and by 12th month in 9
patients(p-value: 0.004). Baseline endobone appearance was
seen in long and ﬂat bones of 11 and 12patients, respectively.
Resolution of long bones endobone appearance was seen in
9patients by 6th month(p-value: 0.008). None of 11patients
had endobone appearance by 12th month(p-value: 0.002),
while ﬂat bone endobone appearance was persistent in
10patients at 12th month. By 6th month, signiﬁcant disap-
pearance of rachitic changes in long bones was seen, how-
ever it was persistent in ribs in 11patients. By 12th month,
there was not any evidence of rickets in ribs and long bones
of any patient(P-values<0.005). Of all subjects with baseline
skull base sclerosis, by 6th and 12th month it was persistent in
9(p-value: 0.25) and 5patients(p-value: 0.03) respectively.
The mean metaphysical band to femur length ratio was
signiﬁcantly higher at 6th month compared to the base-
line(7.56  3.66 vs. 2.87  1.25, p-value: 0.001)
Conclusion: This study demonstrated the resolution in
skeletal changes of osteopetrosis after successful HSCT. Long
bones rachitic changes and endobone impression were the
ﬁrst to resolve within 6 months after HSCT.249
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Purpose/Objective(s): Optimal management of pediatric
acute lymphoblastic leukemia (ALL) patients with CNS
involvement remains a challenge, with limited data to guide
treatment. The goal of this study is to evaluate survival and
neurocognitive outcomes among pediatric ALL patients with
CNS involvement who underwent stem cell transplantation
(SCT) and received cranial or craniospinal irradiation in
addition to total body irradiation (TBI) as pre-transplant
preparative regimen according to an institutional protocol.
Materials/Methods: A retrospective analysis was performed
of pediatric ALL patients with CNS involvement who under-
went SCT at our institution between 1986 and 2011. The
Kaplan-Meier method was used to compute estimates of
disease-free survival (DFS). Cox regressionmodels were used
to determine associations of patient and disease character-
istics and treatment methods.
Results: Forty-one pediatric ALL patients underwent SCT
with TBI as a preparative regimen and received additional
cranial or craniospinal irradiation due to CNS involvement.
Median age at diagnosis was 5 years (range 1 to 21 years).
Twenty-six patients were standard-risk by NCI criteria, and
14 were high-risk. Five patients underwent transplant in
ﬁrst complete remission (CR), 25 in CR 2, and 11 in CR 3 or
greater. All patients received a cranial boost; median cranial
dose was 24 Gy (range 18-35.4 Gy). Eighteen patients
received a spinal boost; median spinal dose for these pa-
tients was 18 Gy (range 15-24.6 Gy). Survival analysis from
date of SCT revealed a 1 year DFS of 78%, 2 year 67%, and 5
year 67%. Univariate Cox regression revealed no statistically
signiﬁcant associations; however, omission of a spinal
boost was associated with inferior DFS (HR 3.23, p¼0.14). A
combined CNS and bone marrow relapse prior to transplant
was associated with an inferior DFS (HR 3.64, p¼0.11), as
compared with an isolated CNS relapse. 17/41 patients had
an isolated CNS relapse, and analysis of these patients
revealed a 1 year DFS of 88%, 2 year 81%, and 5 year 74%. A
battery of neurocognitive testing was performed in 16 pa-
tients and at a mean of 4.4 years after transplant, mean
post-transplant overall IQ was 103.7 (range 84-143). Pre
and post-transplant neurocognitive testing in a subset
revealed a mean overall IQ change of +4.8 points (range -1
to +9).
Conclusions: We show that addition of craniospinal irra-
diation to TBI is feasible in the preparative regimen for SCT
in children with CNS leukemia and is associated with
favorable DFS at 5 years post transplant, particularly in
those patients with isolated CNS relapse. The use of cra-
niospinal as opposed to cranial irradiation may be impor-
tant in maximizing disease control. Post-transplant
neurocognitive testing reveals average intelligence. Pre and
post-transplant testing shows no change in IQ scores,
though numbers remain small. CSI plus TBI is worthy of
further protocol investigation.
